Donate
T1International Statement on Appointments by President-elect Biden

T1International Statement on Appointments by President-elect Biden

Facebook Google LinkedIn Twitter

On November 16, it was first reported that President-elect Biden will appoint Steve Ricchetti as one of his counselors in the White House. We are disappointed that the President-elect would choose a former lobbyist for Eli Lilly and Sanofi to serve in such a senior post in his administration.

President-elect Biden has made lowering drug prices, including insulin prices, a centerpiece of his messaging since he launched his campaign. This type of appointment signals to the millions of Americans who depend on insulin to survive that the incoming Biden Administration is not going to make solving the insulin crisis a priority. The diabetes community does not need more political theater or empty words. We need affordable insulin.

With that in mind, the selection of California Attorney General Xavier Becerra to serve as Secretary of Health and Human Services, first reported on December 6, is more encouraging. Attorney General Becerra has worked tirelessly to defend the Affordable Care Act from the most recent efforts to strike it down, and has expressed support for using administrative action such as march-in rights to lower the price of prescription drugs. If he is confirmed, we would encourage Attorney General Becerra to use the powers available to him as Secretary of Health and Human Services to make insulin and other medicines more affordable in the first days of the new administration.

As the president-elect continues to select people to staff his administration, we encourage him to appoint people to key health posts in the mold of Attorney General Becerra, who do not have ties to the pharmaceutical industry and who are prepared to take the bold action necessary to tackle the twin crises of high drug prices and the COVID-19 pandemic.

Related posts:

T1International Statement on Freeze of Executive Actions

T1International Statement on Freeze of Executive Actions

On January 20, President Biden issued a freeze on all new regulations that former President Trump had not finished implementing so his administration would have a chance to evaluate them and decide whether they should go into effect. These freezes are standard practice for a new administration taking over for a president of the opposite party; President Trump implemented a similar freeze on his first day in office in 2017. Read more

T1International Statement on Lawsuit to Overturn the Affordable Care Act

T1International Statement on Lawsuit to Overturn the Affordable Care Act

On November 10, the Supreme Court will hear oral arguments in California v. Texas, a case that could invalidate the Affordable Care Act (ACA). Since it was signed into law in 2010, the ACA has provided critical protections to the diabetes community in the United States. Now, a group of 18 states led by Texas are arguing that a single change to the law passed as part of the 2017 Tax Cuts and Jobs Act has rendered the entire law unconstitutional, even though there is no evidence that this was an outcome Congress intended at the time. If the Supreme Court rules in favor of Texas, the entire ACA could be ruled unconstitutional. Read more

T1International Statement on Executive Orders

T1International Statement on Executive Orders

On Friday afternoon, President Trump released four executive orders intended to lower drug prices, including two targeted directly at lowering the cost of insulin for patients who rely on it. Despite his assertion that these orders are intended to “completely restructure the prescription drug market,” these orders will not do anything to fix the underlying cause of the insulin crisis in America. Patients will still need to wait months for the rulemaking process to run its course, and likely even longer after that if these orders end up in court. While T1International USA is glad that the administration has stated that making insulin more affordable is a priority, these orders miss the mark. We don’t need incremental bureaucratic steps as an election approaches - we need transformative change that will make our medicine more affordable now. Read more

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International is outraged, though not surprised, to see pharmaceutical companies once again put profit over human lives. On Tuesday, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the state of Minnesota to challenge the Alec Smith Insulin Affordability Act. Read more